Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:16:17.331Z.
Calculation as of: 2026-10-06T14:16:17.331Z.
Quote observation: 2026-10-06T14:14:34.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 781bf18d5b555faf6525e3bbfdfcc877af608ad86c98afd042bd19dc8220ce7c
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$146.22M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$156.62M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cardiol Therapeutics Inc. (CRDL) | $153.31M | N/A | N/A | N/A | N/A |
| Codexis, Inc. (CDXS)vs › | $152.20M | N/A | 1.29% | 1.28% | 1.28% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.22M | N/A | N/A | N/A | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $146.71M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $156.62M | N/A | N/A | N/A | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $156.15M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $144.79M | N/A | N/A | N/A | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $156.09M | N/A | N/A | N/A | N/A |
| Inogen, Inc. (INGN)vs › | $159.88M | N/A | 4.75% | 3.30% | 2.87% |
| LifeMD, Inc. (LFMDP)vs › | $142.72M | N/A | 0.81% | 0.81% | 0.81% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
